Chronic myelogenous leukemia: from molecular biology to clinical aspects and novel targeted therapies.
about
Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era.An overview of chronic myeloid leukemia and its animal models.Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia.Identification of target genes using gene expression profile of granulocytes from patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells.
P2860
Chronic myelogenous leukemia: from molecular biology to clinical aspects and novel targeted therapies.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Chronic myelogenous leukemia: ...... and novel targeted therapies.
@ast
Chronic myelogenous leukemia: ...... and novel targeted therapies.
@en
type
label
Chronic myelogenous leukemia: ...... and novel targeted therapies.
@ast
Chronic myelogenous leukemia: ...... and novel targeted therapies.
@en
prefLabel
Chronic myelogenous leukemia: ...... and novel targeted therapies.
@ast
Chronic myelogenous leukemia: ...... and novel targeted therapies.
@en
P356
P1476
Chronic myelogenous leukemia: ...... and novel targeted therapies.
@en
P2093
Koiti Inokuchi
P304
P356
10.1272/JNMS.73.178
P577
2006-08-01T00:00:00Z